Fecal Microbiota Transplantation (FMT) to Slow Biological Aging (LONGEVIBIOME)
A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.
The goal of this clinical trial is to evaluate if multi-dose fecal microbiota transplantation (FMT) capsules can safely and effectively slow down biological aging and reduce chronic low-grade inflammation in adults aged 45 to 80 with metabolic neglect.
The main questions it aims to answer are:
- Can oral FMT capsules significantly slow the biological pace of aging as measured by the DunedinPACE epigenetic clock?
- Can FMT successfully reduce chronic systemic inflammation (measured by markers such as suPAR, IL-6, and hs-CRP)?
Researchers will compare participants receiving the active product to those receiving a matching placebo to see if the microbiome intervention improves metabolic health and cognitive function via the gut-brain axis.
Participants will:
- Undergo a short-term preparation phase involving targeted antibiotics and standard bowel cleansing.
- Receive an 2 initial induction doses of active product (or placebo) followed by 5 regular booster cycles administered approximately every 4 weeks.
- Attend periodic clinical visits for physical examinations, blood draws, stool sample collection (at home), and cognitive testing using the CANTAB platform and MoCA scale.
- Maintain a participant diary to record adverse events (AE), product administration, stool sample collection, and dietary habits.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Voluntary written informed consent signed prior to any study-related procedures.
- Age between 45 and 80 years (inclusive) at the time of screening.
- Classified as "metabolically neglected" with documented pre-disease conditions or regulated early-stage chronic disorders.
- Accelerated biological aging rate 1.1, OR between 1.05 and 1.099 combined with chronic low-grade inflammation (inflammaging).
- Preserved cognitive function with a Montreal Cognitive Assessment (MoCA) score between 24 and 30 points.
- Physical ability to perform computerized cognitive tests on a touch-screen tablet.
- Commitment to maintaining stable dietary and physical activity habits throughout the study period.
- Possession of a home freezer and ability to strictly comply with cold-chain storage logistics for investigational products and stool samples.
- Demonstrated ability to swallow large capsules.
- Adequate baseline laboratory parameters (such as blood counts and kidney function).
- For women of childbearing potential: agreement to use a highly effective method of contraception throughout the study and for 30 days post-intervention.
- Readiness to ensure presence at the registered home address to receive scheduled frozen-chain courier shipments.
Exclusion Criteria:
- Systemic antibiotic therapy within 12 weeks prior to baseline.
- Supplementation with any commercial pre- or probiotics within 4 weeks prior to baseline.
- Diagnosed malignancy within the past 5 years (except fully cured basal cell carcinoma or cervical cancer in situ).
- Participation in any other clinical study or trial within 30 days prior to consent or during this study.
- Pregnancy, breastfeeding, or planning a pregnancy during the study and for 30 days post-intervention.
- Known hypersensitivity, intolerance, or allergy to any component of the investigational product (MBiotix HBI Caps), placebo, preparation antibiotics (Neomycin, Metronidazole), antibiotic placebo, or bowel cleansing solution (macrogols).
- Pre-existing hearing loss, chronic tinnitus, or diagnosed vestibular disorder. History of or active peripheral neuropathy of any etiology.
- Myasthenia gravis or other neuromuscular transmission disorders.
- Concurrent, ongoing use of loop diuretics, other aminoglycoside antibiotics, or known nephrotoxic drugs.
- Severe, unstable, or uncontrolled comorbidities, including NYHA Class III/IV heart failure, unstable angina, or myocardial infarction within the past 6 months.
- Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR < 30 mL/min/1.73 m²).
- Active, severe psychiatric disorders (e.g., severe depression with active suicidal ideation, psychotic disorders, unstable bipolar disorder).
Diagnosis of progressive neurodegenerative diseases (Parkinson's, Alzheimer's) or moderate-to-advanced dementia.
- Active, clinically significant inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other severe gastrointestinal disorders.
- Evidence of gastrointestinal mucosal damage (ulceration, perforation, bleeding) within 7 days prior to the first product dose.
- Clinically significant immunosuppression, including chronic systemic corticosteroids, HIV infection with a CD4+ cell count < 200/µl, history of solid organ or hematopoietic stem cell transplantation.
- Active infection requiring antibiotics during the induction phase or anticipated antibiotic use during the first 7 days post-induction.
- Prior fecal microbiota transplantation (FMT) treatment for indications other than recurrent C. difficile infection.
- Significant dysphagia precluding safe capsule ingestion.
- Inadequate baseline laboratory parameters (such as blood counts and kidney function).
- Any medical condition or circumstance judged by the Principal Investigator to compromise participant safety or protocol adherence.
- Anticipated inability to comply with study procedures, such as missing scheduled follow-up visits, lacking reliable home freezer storage, or having a lifestyle/occupation that prevents proper cold-chain product handling or consistent attendance.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:MBiotix HBI Caps
MBiotix HBI Caps (FMT capsules) + Preparation antibiotics (Neomycin and Metronidazole) + Standard bowel cleansing (Macrogols). Participants receive targeted preparation antibiotics followed by bowel cleansing, and then a multi-dose regimen of fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) in an initial induction phase and subsequent booster cycles. |
Fecal microbiota transplantation (FMT) capsules administered in an initial induction phase followed by subsequent booster cycles. Frozen oral capsules containing full-spectrum human gut microbiota given as an initial induction (comprising a single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks. |
|
プラセボコンパレーター:Placebo
Placebo Capsules (matching MBiotix HBI Caps) + Antibiotics Placebo (matching two active antibiotics) + Standard bowel cleansing (Macrogols). Participants receive matching placebo treatments for both the preparation antibiotics and the oral capsules (MBiotix HBI placebo), along with the same standard bowel cleansing and multi-dose schedule (an initial induction phase and subsequent booster cycles). |
Placebo Capsules (Comparator): Frozen oral capsules identical in appearance, packaging, and dosing schedule to the active product, containing pharmacologically inert substances. Administered as an initial induction phase (single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Clinical and Biological Response (Responder Rate)
時間枠:Baseline, Week 13, and Week 26
|
The primary outcome is the proportion of participants categorized as "Responders" following multi-dose fecal microbiota transplantation (MBiotix HBI Caps) compared to placebo. A participant is classified as a Responder if they demonstrate objective physiological improvement from Baseline to Week 13 and/or Week 26, defined as meeting at least one of the following two pre-specified criteria:
Results will be reported as the percentage of participants in each treatment arm meeting this composite response definition. |
Baseline, Week 13, and Week 26
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 13/HBI/2026
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。